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Abstract19
In equine and racing practice, detomidine and butorphanol are commonly used20
in combination for their sedative properties. The aim of the study was to21
produce Detection Times to better inform European veterinary surgeons, so that22
both drugs can be used appropriately under regulatory rules. Three independent23
groups of 7, 8 and 6 horses, respectively, were given either a single intravenous24
administration of butorphanol (100 g/kg), a single intravenous administration25
of detomidine (10 g/kg) or a combination of both at 25 (butorphanol) and 1026
(detomidine) g/kg. Plasma and urine concentrations of butorphanol,27
detomidine and 3-hydroxydetomidine at predetermined time points were28
measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS).29
The intravenous pharmacokinetics of butophanol dosed individually compared30
with co-administration with detomidine had approximately a two-fold larger31
clearance (646 ± 137 versus 380 ± 86 ml/hr/kg) but similar terminal half-life32
(5.21 ± 1.56 versus 5.43 ± 0.44 hr). Pseudo-steady-state urine to plasma33
butorphanol concentration ratios were 730 and 560, respectively. The34
intravenous pharmacokinetics of detomidine dosed as a single administration35
compared with co-administration with butorphanol had similar clearance (327836
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±1412 versus 2519 ± 630 ml/hr/kg) but a slightly shorter terminal half-life (0.5737
± 0.06 versus 0.70 ± 0.11 hr). Pseudo-steady-state urine to plasma detomidine38
concentration ratios are 4 and 8, respectively. The 3-hydroxy metabolite of39
detomidine was detected for at least 35 hours in urine from both the single and40
co-administrations. Detection Times of 72 and 48 hours are recommended for41




The combination of detomidine and butorphanol is frequently used in clinical46
equine practice to provide a degree of systemic analgesia alongside sedation for47
minor procedures, such as wound repair or dental work. Whilst they may also48
be used singly, the combination affords better predictability and efficacy with49
lower doses of butorphanol and potentiation of the sedative effect of detomidine50
alone - all in the interests of horse, veterinary surgeon and owner. The use of51
agents, such as α2 agonist sedatives and opioid analgesics, is restricted under the52
rules of international horseracing in order that horses race free from the effects53
of medication. However, use of therapeutic medications to treat racehorses out54
of competition is legitimate. Therefore, to deal with the race-day scenario55
where a horse competes having received medication in its training programme,56
the term “free from the effects of medication” has to be defined. One such57
definition can be a drug concentration in blood plasma that is less than the58
concentration required for a significant therapeutic effect. Toutain & Lassourd,59
2002 proposed an approach based upon the above definition that also takes into60
account variation in both pharmacokinetic (PK) and pharmacodynamic (PD)61
parameters for a population of horses. An estimate of the irrelevant plasma62
concentration (IPC) is based upon a pharmacologically effective plasma drug63
concentration divided by an appropriate safety factor. Also, with knowledge of64
urine PK parameters an irrelevant urine concentration (IUC) can also be65
estimated. The IPC and IUC can be used for the purpose of deriving drug66
screening limits, which in turn, can be used in conjunction with drug67
elimination profiles to obtain appropriate detection times (DT) for the matrices68
concerned. The DT is the time post last therapeutic administration when the69
plasma and urine drug concentrations for all horses in the study drop below the70
IPC and IUC.71
Detomidine is an α2-agonist, used as a sedative primarily in horses, and is72
usually available as the salt detomidine hydrochloride (Elfenbein et al., 2009).73
Machnik et al., 2006 described an intravenous (IV) PK study of detomidine74
hydrochloride and its metabolites 3-hydroxydetomidine and 3-75
carboxydetomidine at a dose of 20 g/kg in ten horses for the purposes of76
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developing a detection time. Grimsrud et al., 2009 published a two way cross77
over study that investigated the PK of detomidine and its metabolites from both78
IV and intramuscular (IM) administrations at a dose of 30 g/kg in eight horses.79
Hubbell et al., 2009 reported the effect of the timing of the administration of80
detomidine relative to physical exertion by administering the drug IV at a dose81
of 40 g/kg either at rest or one minute after exercising on a treadmill.82
Butorphanol is a synthetic opioid analgesic and is used for pain relief in horses.83
It is administered either IM or IV and is also commonly paired with sedatives84
such as detomidine, to provide analgesia in addition to sedation during85
veterinary procedures. Hannan et al., 2004 described an IV PK study of86
butorphanol tartrate at therapeutic dose (100 g/kg) in 6 horses and this was87
followed by Sellon et al., 2008 two-way cross-over study of the88
pharmacokinetics of butorphanol after IV and IM administration (80 g/kg) in89
six horses. Arguedas et al., 2008 reported the PK and physiological/behavioural90
effects of butorphanol after IV and IM administration to six foals aged between91
3 and 8 days. More recently, Knych et al., 2012 reported on the PK/PD of92
butorphanol following intravenous administration to the horse utilising a highly93
sensitive liquid chromatography mass spectrometry (LC-MS) assay.94
Although the individual PK of butorphanol and detomidine have been studied95
extensively there is no reported PK for the intravenous PK of butorphanol and96
detomidine administered in combination. The purpose of the study presented97
herein was to determine the plasma and urine PK of detomidine and98
butorphanol co-administered using a highly sensitive LC-MS/MS method and99
compare to the PK of individual IV administrations of butorphanol and100
detomidine at their respective clinical doses in the horse. Furthermore, this101
study will give guidance on the withdrawal time of butorphanol and detomidine102




Seven healthy Thoroughbred geldings aged 4-10 years (mean bodyweight 504107
kg) were used for the individual administered butorphanol tartrate study carried108
out at Ballybrown Equine Clinic, Calrina, Limerick, Ireland. Eight healthy109
Standardbred geldings/mares aged 6-16 years (mean bodyweight 638 kg) were110
used for the individual administered detomidine hydrochloride study carried out111
at the Institute of Biochemistry, Cologne, Germany. Six healthy Thoroughbred112
geldings aged 4-8 years (mean bodyweight 504 kg) were used for the co-113
administration of butorphanol tartrate and detomidine hydrochloride study114
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carried out at the British Horseracing Authority’s Centre for Racehorse Studies,115
Newmarket, UK.116
117
Drug administration and sampling118
All administration and sampling studies were carried out with ethical approval119
from the country specific animal research authority. A 14 gauge catheter was120
placed in the left external jugular vein for sampling and the drug administered121
into the right jugular vein. Drug doses for the different studies were; 100 and 10122
g/kg for the individual administrations of butorphanol and detomidine123
respectively, and 25 and 10 g/kg for the combination administration of124
butorphanol and detomidine, respectively. For the combination study125
detomidine hydrochloride was given 5 minutes after butorphanol tartrate126
administration.127
Pre-dose blood (10 mL) and urine (20 mL) were collected as control samples.128
Post dose blood (10 mL) and urine (20 mL) were collected at decreasing129
frequencies as described in Supplementary Tables 1-3. Catheters were removed130
following collection of the 24 h post dose blood sample and the remaining131
samples collected by direct venepuncture. All urine samples were obtained132
using the free catch method. Blood was centrifuged for 10 minutes and plasma133
stored at -20ºC until analysis. Urine was frozen immediately and stored at -20ºC134
and centrifuged post thaw prior to analysis.135
Sample Bioanalysis:136
Samples obtained following administration of butorphanol, detomidine and137
butorphanol/detomidine were analysed, respectively at: BHP Racing Laboratory,138
Limerick, Ireland, the Institute of Biochemistry, Cologne, Germany and LGC,139
Fordham, UK. The analytical methods were validated to ensure suitable precision140
and accuracy, lower limit of quantification (LLOQ), linearity, calibration range141
and selectivity (see results section). Supplementary Tables 4 and 5 detail the142
sample preparation/extraction and instrumental conditions respectively that were143
used by each laboratory. In addition to concentrations of ‘parent’ detomidine and144
butorphanol in plasma and urine, concentrations of 3-hydroxydetomidine were145
also measured since urinary concentrations of this metabolite were more146
abundant than parent drug; this making it a more suitable target analyte for any147
subsequently applied routine drug screening procedures (Machnik et al., 2006).148
Detomidine is also metabolised to 3-carboxydetomidine in the horse. However,149
this metabolite was not chosen for quantification since its chemical properties150
make it potentially less suitable for inclusion in subsequent routine drug screening151
procedures that may differ between laboratories.152
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Pharmacokinetic Analysis153
Pharmacokinetic analyses were conducted using non-compartmental (NCA) and154
non-linear mixed effects methods (NLME) with Phoenix WinNonlin 8.1155
(Pharsight Corporation, Cary, NC). The 2-stage NCA approach firstly involved156
the estimation of clearance (CL), terminal volume of distribution (Vdz), half-life157
(T1/2), mean residence time (MRT) and steady-state volume of distribution (Vss)158
for butorphanol and detomidine. Secondly, statistical t-tests were performed on159
the log transformed pharmacokinetic parameters for (i) butophanol dosed160
individually versus in combination with detomidine and (ii) detomidine dosed161
individually versus in combination with butorphanol to determine any162
differences. Compartmental NLME PK models were applied to the plasma163
concentration data including below the limit of quantification (BLQ) values.164
Residual error was modelled on a proportional error model. An exponential165
random effect model was chosen to describe inter-individual variability e.g.166
parameter = typical parameter * exp(eta). A categorical covariate for individual167
versus combination administration was implemented on the model parameters168
in a multiplicative exponential way. The model analysis started from the basic169
compartmental models without the covariate. Next, the contribution of the170
covariate to the PK parameters was assessed by a reduction in the objective171
function using stepwise forward inclusion. Selection of the best model was172
based on the lowest value of the Akaike and Bayesian Information Criteria (AIC173
and BIC), chi-square p-value based on the likelihood ratio test, visual inspection174
of the population predicted concentration versus the observed concentrations175
and the resulting conditional weighted residual errors. Finally, the best model176
was checked for robustness using a bootstrap resampling method. The effective177
plasma concentration (EPC) and irrelevant plasma and urine (IPC and IUC)178
were estimated using the Toutain and Lassourd, 2002 methodology. Briefly, the179
EPC was estimated from the dose divided by the mean plasma clearance over a180
24 hour period. The IPC was determined by dividing the EPC by a factor of 500181
and the IUC determined by multiplying the IPC by the pseudo steady-state ratio182
of urine to plasma concentration (Rss). The detection time was determined by183
the time post dose where all horses had concentrations below the IPC and IUC.184
Montecarlo simulations were used to determine a 95%/95% tolerance interval185
for a withdrawal time.186
Results187
Sample Bioanalysis188
Following validation, the analytical methods were deemed suitable for189
application to the study samples. Specifically, inter- and intra-batch precision190
(% coefficient of variation) and accuracy (% relative error) were within 20%191
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(25% at the LLOQ), linearity of dilution (% relative error and % coefficient of192
variation) was within 20% and no significant matrix suppression or193
interferences were observed. Supplementary Table 6 summarises the resulting194
calibration ranges, LLOQs and sample dilution ranges that were validated for195
each method. LLOQs (LOD) for butorphanol and detomidine in plasma and196
urine were 10 (2) and 100 (10) pg/ml, respectively.197
Intravenous plasma and urine pharmacokinetics for butorphanol tartrate (100198
g/kg) dosed individually199
The plasma and urine PK profiles for butorphanol tartrate dosed at 100 g/kg as200
a single IV administration are displayed in Figures 1 and 2, respectively, as red201
symbols and connecting dashed lines. The plasma decay curves appear to have202
three phases of decline entering into the third phase at approximately 5 hours.203
The urine PK curves display a rapid increase followed by single phase decay.204
The ratio of urine to plasma concentration at pseudo steady-state (Rss) is205
approximately 730.206
Intravenous plasma and urine pharmacokinetics for butorphanol tartrate (25207
g/kg) co-administered with 10 g/kg detomidine hydrochloride208
The plasma and urine PK profiles for butorphanol tartrate dosed at 25 g/kg in209
combination with 10 g/kg detomidine hydrochloride as an IV administration210
are displayed in Figures 1 and 2, respectively, as black symbols and solid211
connecting lines. The plasma decay curves appear to have two phases of decline212
entering into the second phase at approximately 3 hours. The urine PK curves213
display a rapid increase followed by single phase decay. The ratio of urine to214
plasma concentration at pseudo steady-state (Rss) is approximately 560.215
Butorphanol Plasma PK Analysis216
Table 1 displays the average plasma NCA PK parameters with standard217
deviations computed from the PK profiles and suggests that in this study218
butorphanol co-administered with detomidine has a statistically lower clearance219
(p <0.05) and longer mean residence time (MRT) (p <0.05) when compared to220
butorphanol dosed on its own at 100 g/kg . However, there was no significant221
difference between terminal half-life or steady-state volume of distribution222
(Vss) which are approximately 5 hours and 1 L/kg in both cases, respectively.223
The most parsimonious NLME model obtained was a 3 compartment model,224
random effects included on all parameters with partial correlation (V1,CL1,V3225
and CL2,V2) with the covariate implemented on the parameters clearance from226
the central compartment (CL1) and distribution clearance to and from the third227
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compartment (CL3). The influence of the covariate for individual versus228
combination administration on CL1 and CL3 are as follows:229
CL1 = Typical Value * exp(-0.666 * (administration=1)) * exp(CL1eta)230
CL3 = Typical Value * exp(-2.16 * (administration=1)) * exp(CL3eta)231
Where the Typical Value (TV) is the population fixed effect value for the232
parameter and administration = 1 refers to the case for combination233
administration.234
Table 2 shows the outputted PK parameters for the most parsimonious model235
which were encompassed by the 2.5 and 97.5% confidence intervals of the236
bootstrap resampling analysis. Clearance values were similar between the NCA237
and NLME approaches for both combination and individual administrations.238
Butorphanol Irrelevant Plasma and Urine Concentration (IPC and IUC)239
Estimated EPC and IPC values for combination administration (2,692-2,741240
pg/ml and 5-6 pg/ml respectively) were approximately half that for individual241
administration (5,995-6,450 pg/ml and 12-13 pg/ml respectively) see242
Supplementary Table 7. Plasma DTs were consistent between combination (>47243
hours) and individual administration (49 hours) although no definitive value244
could be given for the combination administration due to the IPC being below245
the LLOQ. Urine DT for individual administration (57 hours) was similar to246
combination administration (50 hours).247
Intravenous plasma and urine pharmacokinetics for detomidine hydrochloride248
(10 g/kg)249
The plasma and urine PK profiles for detomidine hydrochloride dosed at 10250
g/kg as a single IV administration are displayed in Figures 3 and 4,251
respectively, as red symbols and dashed connecting lines. The plasma decay252
curves appear to follow a single exponential decay. The urine PK curves display253
only a few time points due to low concentrations of detomidine. The ratio of254
urine to plasma concentration over the 2 to 6 hour range is approximately 4.255
Intravenous plasma and urine pharmacokinetics for detomidine hydrochloride256
(10 g/kg) co-administered with 25 g/kg butorphanol tartrate257
The plasma and urine PK profiles for detomidine hydrochloride dosed at 10258
g/kg in combination with 25 g/kg butorphanol tartrate as an IV259
administration are displayed in Figures 3 and 4, respectively, as black symbols260
and solid connecting lines. The plasma decay curves appear to have two phases261
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of decline, however, the first phase is not explicit. The urine PK curves display262
limited time points due to low concentrations of detomidine. The ratio of urine263
to plasma concentration over these time points is approximately 8.264
Detomidine Plasma PK Analysis265
Table 3 displays the average NCA PK parameters with standard deviations and266
suggests in this study that detomidine co-administered with butorphanol has a267
statistically longer half-life (p<0.05) but statistically shorter MRT (p<0.05)268
when compared to detomidine dosed on its own. However, there is no269
significant difference for the parameters clearance and Vss between single and270
co-administration of detomidine. The most parsimonious NLME model271
obtained was a simple 1 compartment model, random effects included on272
clearance only but not volume of distribution and no significant effect of the273
covariate i.e. individual versus combination dosing. Table 4 shows the outputted274
PK parameters for the most parsimonious model which were encompassed by275
the 2.5 and 97.5% confidence intervals of the bootstrap resampling analysis.276
Clearance values were similar between the NCA and NLME approaches for277
both combination and individual administrations.278
Detomidine Irrelevant Plasma and Urine Concentration (IPC and IUC)279
Estimated EPC and IPC values for individual administration (127-132 pg/ml280
and 0.25-0.26 pg/ml respectively) and combination administration (128-165281
pg/ml and 0.27-0.33 pg/ml respectively) were similar (see Supplementary Table282
8). The estimated IPC values are sub pg/ml and therefore plasma DT could not283
be confirmed; > 4 hours for individual administration and > 9 hours for284
combination administration. Urine DT for individual administration could not285
be confirmed (> 4 hours), however, a urine DT of 11 hours was confirmed for286
the combination administration.287
Plasma and urine pharmacokinetic profiles for 3-hydroxydetomidine resulting288
from the metabolism of detomidine hydrochloride289
The plasma and urine PK profiles for the metabolite 3-hydroxydetomidine are290
displayed in Figures 5 and 6. The plasma profiles are characterised by an initial291
increase followed by a two phase decline and the concentration of the292
metabolite from the single administration of detomidine appears to be higher293
than the concentrations resulting from the combination with butorphanol. The294
urine profiles are characterised by a slow increase in metabolite leading to a flat295
phase followed by a single phase of decline. The urine concentrations of296
metabolite from the single administration of detomidine initially appear to be297
lower than the urine concentrations resulting from the combination with298
butorphanol, however, after 20 hours post dose the concentrations are similar.299
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Discussion300
The analytical methods applied in the current study are significantly more301
sensitive than those previously applied for determining the disposition of302
detomidine and butorphanol in the horse. The LLOQs (supplementary Table 6)303
for butorphanol, detomidine and 3-hydroxydetomidine in plasma from the304
current study range between 5 and 10 pg/ml, which are significantly lower than305
previously reported. The LLOQs (supplementary Table 6) for butorphanol,306
detomidine and 3-hydroxydetomidine in urine from the current study range307
between 10 and 100 pg/ml. Compared to plasma, there are fewer existing308
reports that measure the concentrations of these analytes in urine. However, the309
urine LLOQs for the detomidine derived analytes in the current study are at310
least 100-fold lower than reported previously (Machnik et al., 2006). The311
significantly enhanced analytical sensitivity provided by the methods applied312
herein permits a lengthened window of detection for all of the analytes. In turn,313
it is anticipated that this should permit a more accurate assessment of the PK314
disposition of the drugs at the later time points. Furthermore, the concurrent315
measurement of plasma and urine concentrations allows for the calculation of316
plasma to urine drug ratios, which enables urinary drug concentrations to be317
used as surrogates for plasma concentrations when regulating the use of these318
medications.319
Ideally a three-way cross over study in the same horses should be carried out in320
order to compare the PK between butorphanol and detomidine single321
administrations and their co-administration. This would be a very expensive322
study for any one research centre and there would likely be ethical issues arising323
from multiple administration of this nature to the same animal in the timescales324
needed to provide scientifically robust data. A collaboration was therefore put in325
place via the European Horserace Scientific Liaison Committee (EHSLC) to326
combine data from three separate studies. Although this is not a cross over study327
it does allow the finding of any gross changes in the PK between single328
administration and co-administration.329
Both the NCA and NMLE approaches in the herein study suggest that the330
clearance of butorphanol in combination with detomidine is approximately half331
that for an individual butorphanol administration. This is further supported by332
the Knych et al., 2012 study where the clearance for butorphanol dosed333
individually was estimated to be 690 ±150 ml/hour/kg i.e. approximately twice334
that of the combination clearance. However, there was no significant difference335
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in the butorphanol terminal half-lives which were superimposable (Figures 1336
and 2) and suggests that the terminal half-life is influenced by a physiological337
compartment in the horse that can be saturated and represents only a small338
percentage of the area under the plasma curve (AUC). Despite the butorphanol339
dose administration being four times greater for a single administration340
compared to the clinical dose when co-dosed with detomidine the difference in341
AUC was only 2 fold. This pharmacokinetic advantage probably contributes to342
the lower dose required for butorphanol to be efficacious in combination with343
the alpha-2-agonist.344
The Toutain and Lassourd (2002) methodology estimates an irrelevant plasma345
concentration (IPC) for a drug using both the IV therapeutic dose and clearance346
when dosed individually. The IPC for butorphanol dosed in combination with347
the alpha-2-agonist is approximately 2 fold lower than that for butorphanol348
dosed on its own because of differences in both dose and clearance. While the349
plasma DT can be confirmed for butorphanol dosed individually (51 hours) it350
cannot be confirmed for combination administration (>47 hours) due to the IPC351
being below the LLOQ. However, if a plasma screening limit can be set at 10352
pg/ml based on risk management then a withdrawal time can be estimated for353
both butorphanol dosed individually or in combination with detomidine using354
the NLME model as the model includes BLQ data. A withdrawal time of 72355
hours was estimated for a screening limit of 10 pg/ml based upon the predicted356
tolerance interval representing 95% confidence of the 95th percentile using357
montecarlo simulation.358
For the purposes of detecting butorphanol in horse, analysis in urine gives359
concentrations that are 730 and 560 times higher than the corresponding360
concentrations in plasma at pseudo steady-state (Rss) for administration of361
butorphanol alone and co-administered, respectively. This makes urine a very362
good matrix for butorphanol screening with similar DT but a 3 fold difference363
in the IUCs for individual administration and co-administration with364
detomidine. Pragmatically only one screening limit can be used to control for365
butorphanol administration, fortunately, the use of 3 ng/ml as a urine screening366
limit gives the same detection times as determined in Supplementary Table 7.367
Therefore a detection time of 72 hours will comfortably control for butorphanol368
administration either individually or in combination with detomidine.369
Butorphanol appears to have no significant effect on the pharmacokinetics of370
detomidine. Whilst there is a statistically shorter plasma half-life for detomidine371
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dosed on its own at 10 g/kg compared with detomidine dosed with 25 g/kg372
butorphanol there is no statistical difference between the clearance values.373
Furthermore, the MRT for detomidine single administration is statistically374
longer compared to the detomidine combination which is inconsistent with an375
inhibitory drug-drug interaction. This is supported by the NMLE model where376
the most parsimonious model did not include the covariate for individual versus377
combination administration.378
Based upon the Toutain and Lassourd approach the plasma IPC (and therefore379
the plasma screening limit) for both detomidine and detomidine dosed in380
combination with butorphanol will be the same as the clearance values are not381
statistically different. However, the estimated IPC values are less than 1 pg/ml382
which is too low for routine screening of a blood sample using current383
technologies.384
Analysis of detomidine in urine gives concentrations that are only 4 (detomidine385
alone) and 8 (detomidine in combination with butorphanol) times higher than386
the corresponding concentrations in plasma at pseudo steady-state (Rss).387
Furthermore, urine data is variable and combined with the relatively low Rss388
values suggests that urine is also a poor matrix for detomidine detection.389
European rules of racing require a minimum of 48 hours between administration390
and competition and given that detomidine has a very short half-life (< 1 hour),391
monitoring of parent detomidine is of limited use. However, the 3-hydroxy392
metabolite of detomidine gives consistent concentrations in plasma and very393
high concentrations in urine. Therefore, detection of the 3-hydroxy metabolite394
in urine offers an excellent way forward for the controlling of detomidine395
administration with a screening limit of 100 pg/ml controlling for at least 35396
hours post detomidine administration.397
The data herein suggests that either detomidine impacts on the398
pharmacokinetics of butorphanol or that butorphanol’s clearance is dose399
dependent between 25-100 g/kg. For the latter scenario, the clearance is400
smaller at the lower dose which is hard to rationalise, however, a dose response401
PK study with butorphanol alone would answer this question. For the former402
scenario, a three-way cross over study in the same horses should be investigated403
with the butorphanol/detomindine combination although this would be a very404
expensive study. Alternatively, a relatively cheap in vitro drug-drug interaction405
study between butorphanol and detomidine using horse microsomes would406
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confirm or not any pharmacokinetic drug-drug interaction. This research407
highlights the need to investigate the pharmacokinetics of drugs administered in408
combination to the horse as potential drug-drug interactions may occur which409
may have a significant effect on both therapeutic and toxic outcomes as well as410
leading to false positives in the control of medications within the equine sports411
industry.412
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Table 1: Pharmacokinetic parameters for butorphanol tartrate dosed at 100469






















Regimen CL (mL/hr/kg) VdZ (L/kg) T1/2 (hr) MRT (hr) Vss (L/kg)
100 g/kg 646 ± 137 5.07 ± 2.48 5.21 ± 1.56 1.45 ± 0.48 0.97 ± 0.45
25 g/kg (D) 380 ± 86* 2.95 ± 0.38 5.43 ± 0.44 2.63 ± 0.56* 1.01 0.36
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Table 2: NMLE three compartment pharmacokinetic parameters for492
butorphanol tartrate dosed at 100 g/kg as an individual administration and at493
25 g/kg in combination with 10 g/kg detomidine hydrochloride. V1, V2, V3494
represent the volumes of the central, second and third compartments,495
respectively. CL1 represents the clearance from the central compartment and496
CL2 and CL3 represent the distribution clearance between the central497









V1 (mL/kg) 279 276±90.3 322±101
V2 (mL/kg) 471 559±339 479±137
V3 (mL/kg) 221 219±13.4 225±15.8
CL1 (mL/hr/kg) 707 695±118 387±69.7
CL2 (mL/hr/kg) 75 87.2±53.2 77.1±25.8














Table 3: NCA pharmacokinetic parameters for detomidine hydrochloride dosed512
at 10 g/kg as a single administration and in combination with 25 g/kg513
butorphanol tartrate (B).514
515
Regimen CL (mL/hr/kg) VdZ (L/kg) T1/2 (hr) MRT (hr) Vss (L/kg)
10 g/kg 3278 ± 1412 2.76 ± 1.36 0.57 ± 0.06 0.67 ± 0.11 2.32 ± 1.30




















Table 4: NMLE one compartment pharmacokinetic parameters for detomidine534
hydrochloride dosed at 10 g/kg as an individual administration and in535
combination with 25 g/kg butorphanol tartrate. V and CL represent the536









V (L/kg) 2.55 2.55 2.55






















Figure 1: Plasma pharmacokinetic profiles for butorphanol dosed at 100 g/kg559
as a single administration (red dashed line) and at 25 g/kg in combination560
with 10 g/kg detomidine hydrochloride (black solid line)561
562
Figure 2: Urine pharmacokinetic profiles for butorphanol dosed at 100 g/kg as563
a single administration (red dashed line) and at 25 g/Kg in combination with564
10 g/Kg detomidine hydrochloride (black solid line)565
566
Figure 3: Plasma pharmacokinetic profiles for detomidine dosed at 10 g/kg as567
a single administration (red dashed line) and in combination with 25 g/Kg568
butorphanol tartrate (black solid line)569
570
Figure 4: Urine pharmacokinetic profiles for detomidine dosed at 10 g/kg as a571
single administration (red dashed line) and in combination with 25 g/kg572
butorphanol tartrate (black solid line)573
574
Figure 5: Plasma pharmacokinetic profiles for 3-hydroxy detomidine resulting575
from the metabolism of detomidine hydrochloride dosed at 10 g/kg as a576
single administration (red dashed line) and in combination with 25 g/kg577
butorphanol tartrate (black solid line)578
579
Figure 6: Urine pharmacokinetic profiles for 3-hydroxy detomidine resulting580
from the metabolism of detomidine hydrochloride dosed at 10 g/kg as a581
single administration (red dashed line) and in combination with 25 g/kg582
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Supplementary table 1 – Summary of the plasma and urine sample times post administration for butorphanol dosed individually in
each horse (Irish Study)
Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Horse 6 Horse 7 Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Horse 6 Horse 7
Plasma Plasma Plasma Plasma Plasma Plasma Plasma Urine Urine Urine Urine Urine Urine Urine
Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr)
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.83 6.5 1.47 0.05 2 1 0.65
0.08 0.08 0.08 0.08 0.08 0.08 0.08 2.83 14.17 8 0.5 5 1.58 1.25
0.17 0.17 0.17 0.17 0.17 0.17 0.17 6.67 21.25 19.17 1.22 25.83 3.25 3.17
0.25 0.25 0.25 0.25 0.25 0.25 0.25 11.5 25.75 24.08 3 36.75 4.42 4.25
0.3 0.3 0.3 0.3 0.3 0.3 0.3 18 28.5 27.5 6.92 49.75 9.3 7.5
1 1 1 1 1 1 1 27.5 31 30.58 10.08 54 11.67 9.25
2 2 2 2 2 2 2 31.75 54.5 48 13.42 71.75 18.17 12.3
4 4 4 4 4 4 4 56.5 56.25 53.5 20 83.25 22.58 22.47
8 8 8 8 8 8 8 76 73.5 55.75 23.92 97.75 25.08 24
12 12 12 12 12 12 12 83.5 77.75 78.5 25.92 108.25 27.67 24.83
24 24 24 24 24 24 24 99 98 85.25 28.5 120.25 47 26.25
30 30 29 29 28 28 28 110.5 101 96.75 47.75 122.5 51.5 27.75
32 32 31 31 30 30 30 123 104.25 106.75 52.75 124.75 71.25 48.5
50.5 48.75 48.75 48.75 48.75 48.75 48.75 128.5 125.75 123.25 72 143.25 75.5 51.75
74 72 72 72 72 72 72 146 146 125.5 77 146.75 95.25 71.25
98 96 96 96 96 96 96 153.75 148 147 97.25 98 75.25
122 120 120 120 120 120 120 149 153 98.5 100.25 96.25









Supplementary table 2 – Summary of the plasma and urine sample times post administration for detomidine dosed individually in
each horse (German Study)
All horses Horse 207 Horse 208 Horse 215 Horse 217 Horse 229 Horse 257 Horse 281 Horse 282
Plasma Urine Urine Urine Urine Urine Urine Urine Urine
Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr)
0 0 0 0 0 0 0 0 0
1 2.62 2.63 2.6 2.58 2.57 2.53 2.57 2.47
2 4.98 5.03 5.45 5.13 5.05 5.25 4.2 4.28
4 7.82 7.83 7.68 7.75 8.07 8.25 5.25 7.87
8 11.37 11.58 11.27 11.58 1.33 11.42 11.05 11
12 24.48 24.87 24.52 25 25.2 25.42 25.75 25.5
24 35.48 35.83 35.35 35.55 35.47 35.52 35.18 35.1
36 48.4 48.65 48.38 48.72 49 49.13 49.42 49.18
48 59.57 59.98 59.43 59.65 59.67 59.67 59.28 59.2
71.87 72.83 73.12 72.53 74.5 72.08 71.65 71.78
82.98 83.42 83.18 83.12 83 83.17 82.7 82.92
95.88 96.2 95.88 96.2 96.95 96.25 96.35 96.42
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Supplementary table 3 – Summary of the plasma and urine sample times post administration for combination of butorphanol and
detomidine dosed in each horse (UK Study)
Horse 13/11 Horse 14/11 Horse 15/11 Horse 16/11 Horse 17/11 Horse 18/11 Horse 13/11 Horse 14/11 Horse 15/11 Horse 16/11 Horse 17/11 Horse 18/11
Plasma Plasma Plasma Plasma Plasma Plasma Urine Urine Urine Urine Urine Urine
Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr) Time (hr)
-144.08 -142.08 -96.33 -96.32 -89.18 -89.35 -142.17 -138.25 -112.92 -95.47 -22.08 -94
-113.17 -113.33 -72.7 -72.92 -17.33 -17.58 -22.82 -24.08 -90.08 -63.92 -18.17 -21.83
-0.3 -0.22 -0.33 -0.22 -0.33 -0.12 2.48 1.42 1.75 1 1.05 1.78
0.25 0.25 0.25 0.28 0.25 0.25 3.33 3.25 2.5 2.12 1.42 5.08
1 1 1 1.03 1 1 4.75 5.5 3.67 4.28 1.92 11.33
2 2 2 2.07 2.03 1.97 5.8 6.62 6.92 5.87 3 18.83
3 3 3 3.03 3 3 6.77 9.08 9.67 7.12 5.55 23.13
4.08 4.07 4 4.03 4.08 4.08 9.25 11.08 13.17 9.45 6.25 29
5.08 5.08 5 5.03 5.08 5 11.08 14.75 14.58 10.45 8.08 38.83
6 6 6 6.03 6 6 14.75 18.75 18.83 12.45 9.5 50.17
7 7 7 7.03 7.03 7 19.17 23.17 22.83 15.45 10.92 55.17
8 8 8 8.08 8 8 22.67 25.67 26.33 19.62 12.83 74.15
9 9 9 9.08 9 9 24.17 27.25 30.33 22.87 20.17 78.58
11 11 11 11.08 11 11 25.55 30.67 36.58 23.7 25.8 96.7
13 13 13 13.03 13 13 28 33.08 39.75 24.45 28.08 103.17
15 15 15 15.03 15 15 29.45 37.08 46.67 25.12 31.25 120.75
19 19 19 19.03 19 19 30.83 38.92 48.17 26.37 38.5 126.83
23 23 23 23.03 23.03 23 32.83 48.08 54.33 29.37 48.33 143.83
25 25.08 25 25.03 25 25 35.75 54.08 72.67 30.28 54.42 150.72
27 27 27 27.03 27 27 37.08 71.42 79.17 32.53 72.5 169.33
29 29 29 29.03 29.08 29.08 38.5 77 96.83 36.68 77.42 193.75
31 31 31 31.03 31 31 48.25 96.67 105.5 39.12 97.25 222.65
33 33 33 33.03 33 33 53.83 103.92 118.42 39.62 103.42 242.25
35 35 35 35.03 35 35 71.5 120.08 126.67 46.62 119.42
37 37 37 37.12 37 37 77 127.42 147 48.4 125.75
39 39 39 39.08 39 39 97.25 145.22 151.25 54.53 144.42
46.83 46.92 46.67 46.68 46.67 46.65 102.42 150.17 170.8 72.95 149.67
54.42 54.5 54.72 54.77 54.67 54.7 120 174.08 194.83 78.2 169.83
70.5 70.67 70.67 70.7 70.67 70.7 126.33 193.58 222.92 95.12 194.08
78.5 78.5 78.67 78.7 78.5 78.5 145.42 217.75 242.25 102.95 225.25
94.7 94.68 94.67 94.7 94.67 94.83 150.33 241.17 104.87 242.83
102.5 102.48 102.67 102.7 102.83 102.92 174.25 118.87
118.5 118.48 118.67 118.68 118.97 118.75 191.67 126.87
126.5 126.48 126.67 126.68 126.67 126.68 217.65 144.53
143.08 143.12 142.83 142.72 143.08 143.08 241.08 149.87





Supplementary table 4 – Summary of the sample preparation/extraction methods used by each laboratory














To 5 ml of plasma/urine:
- Add medetomidine & D4-3-
hydroxydetomidine internal
standards.
- Add 0.4 mL 4M sodium acetate
buffer + adjust pH to 5.2.
- Add 50 µl Helix pomatia + heat for
1 hour at 50ºC.
- Add 0.5 ml 0.8M sodium
phosphate (pH7), shake and then
centrifuge for 5 mins.
- SPE using Oasis HLB (6 ml, 200
mg).
- Condition with methanol
- Condition with water.
- Apply sample.
- Wash with water.
- Wash with 10% methanol in water.
- Elute with methanol.
- Evaporate, reconstitute in 1 ml
TBME + 0.4 ml 0.06M HC, shake
and then centrifuge for 5 mins.
- Remove the aqueous layer to
LCMS vials.
To 4 ml of plasma:
- Add meperidine internal
standard.
-Add phosphate buffer 0.1 M
pH 5.5 and
centrifuge for 10 mins.
- SPE using Bond Elut Certify
(6 ml, 300mg).
- Condition with methanol
- Condition with phosphate
buffer.
- Apply sample.
- Wash with water.
- Wash with acetate buffer.
- Wash with methanol.
- Elute with ethyl
acetate:triethylamine.
- Evaporate, reconstitute in
50µl methanol + transfer to an
LCMS vial.
To 3 ml of urine:
- Add meperidine internal
standard.
-Add phosphate buffer 0.1 M
pH 5.5, β-glucuronidase from 
helix pomatia & protease+
adjust pH to 6.5.
- Heat at 55 ºC for 1 hour
then centrifuge for 10 mins.
- SPE using Bond Elut
Certify (6 ml, 300mg).
- Condition with methanol
- Condition with phosphate
buffer.
- Apply sample.
- Wash with water.
- Wash with acetate buffer.
- Wash with methanol.
- Elute with ethyl
acetate:triethylamine.
- Evaporate, reconstitute in
100µl methanol + transfer to
an LCMS vial.
To 1 ml of plasma:
- Add medetomidine & D4-3-
hydroxydetomidine internal
standards.
- Add helix pomatia.
- Heat overnight at 45 ºC.
- Add 600 µl 0.1M NaOH in
water.
- Add 3 ml 15% chloroform in
TBME.
- Mix on a rotary mixer for 30
mins then centrifuge for 10
mins.
- Transfer the organic layer to
clean tubes, evaporate +
reconstitute in 5 µl IPA + 100
µl 10 mM ammonium formate,
transfer to LCMS vials +
centrifuge for 10 mins.
To 2 ml urine:
- Add medetomidine & D4-3-
hydroxydetomidine internal
standards.
- Add acetate buffer 1 M pH
4.7, β-glucuronidase from helix 
pomatia & pancreatin.
- Heat overnight at 45 ºC then
centrifuge for 10 mins.
- SPE using Phenomenex
Strata XC (3 ml, 60 mg).
- Condition with methanol
- Condition with water.
- Apply sample.
- Wash with acetate buffer 0.1
M pH 9.0.
- Wash with water.
- Wash with.1 M HCl.
- Wash with methanol.
- Elute with 80 % ethyl acetate:
17 % isopropanol and 3 %
ammonia (v/v).
- Evaporate + reconstitute in 5
µl acetonitrile and 100 µl 10
mM ammonium formate,
transfer to LCMS vials +
centrifuge for 10 mins.
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Supplementary Table 5 – Summary of the instrumental conditions used by each laboratory
Germany Ireland United Kingdom
Instrument
al platform
HPLC = Agilent 1200
MS = AB Sciex 4000 Q-Trap
HPLC = Agilent 1100
MS = Agilent MSD XCT Ion Trap
HPLC = Waters Acquity
MS = AB Sciex 5500 Q-Trap
HPLC
conditions
Column = Phenomenex Gemini 3µ C6-Phenyl 150 x
4.6 mm. Mobile phase A = MeCN and B = 5mM
ammonium acetate (pH 3.5). Flow = 0.5 ml/min.
Gradient = 0% A at 0 mins, held at 0% until 1 mins,
to 100% at 10 mins, held at 100% until 13.5 mins.
Column = Phenomenex Kinetex PFP 100 × 2.1mm,
2.6µm
Mobile phase A = 10mM ammonium acetate and B =
MeCN
Flow = 0.3 ml/min
Gradient = 27% B at 0 mins, rising to 51% at 6 mins,
to 95% at 7 mins, to 27% at 11.1 mins, held at 27%
until 13 mins.
Column = Waters HSS T3 100 x 2.1 mm, 1.8 µm.
Mobile phase A = MeCN & B = 10mM ammonium
formate in water (pH 7.0). Flow = 0.85 ml/min.
Gradient = 0% A at 0 mins, rising to 3.8% at 1.5 mins,
to 6.0% at 1.51 mins, to 20.0% at 2.8 mins, to 24.0%
at 2.81 mins, to 30.0% at 4.2 mins, to 90.0% at 4.21
mins, to 99.9% at 6.20 mins, held at 99.9% until 6.70
mins, to 0% at 6.71 mins, held at 0% until 7.0 mins.
MS/MS
conditions
Turboionspray ionisation in positive mode.
Temperature = 450oC. Ionspray voltage = 5500.
Detomidine = m/z 187 to 81, CE = 29.
3-OH-detomidine = m/z 203 to 185, CE = 21.
Medetomidine (internal standard for detomidine) =
m/z 201 to 68, CE = 49.
D4-3-OH-detomidine (internal standard for 3-OH-
detomidine) = m/z 207 to 81, CE = 35.
Electrospray ionisation in positive mode.
Temperature = 350oC Capillary Voltage = 4000
Butorphanol = 328 to 310 (amplitude = 1.00) to 310 ,
282, 242 (amplitude = 0.47) (combined EIC of all 3
used for quantitation)
Meperidine (internal standard) = 248 to 220,
174(amplitude = 0.94) (combined EIC of 2 ions used for
quantitation)
Turboionspray ionisation in positive mode.
Temperature = 650oC. Ionspray voltage = 5500.
Butorphanol = m/z 328 to 185, CE = 47.
Detomidine = m/z 187 to 81, CE = 13.
3-OH-detomidine = m/z 203 to 81,
CE = 70 (urine) & 17 (plasma).
Medetomidine (internal standard for butorphanol &
detomidine) = m/z 201 to 95, CE = 25.
D4-3-OH-detomidine (internal standard for 3-OH-
detomidine) = m/z 207 to 81, CE = 31.
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Supplementary Table 6 – Validated calibration ranges from each laboratory
Validated calibration ranges and highest validated dilution factors where relevant (calibration line weighting in brackets)
Analyte
Germany (pg/ml) Ireland (pg/ml) United Kingdom (pg/ml)








10 - 10,000 (1/x2)
+ 1000-fold dilution
100 - 10,000 (1/x2)
+ 1000-fold dilution
Detomidine 10 - 2,500 (1/x) 100 - 25,000 (1/x) N/A N/A 5 - 10,000 (1/x
2)
+ 1000-fold dilution
10 - 10,000 (1/x2)
+ 1000-fold dilution
3-Hydroxydetomidine 10 - 2,500 (1/x2)
100 - 25,000 and
25,000 – 200,000
(both lines 1/x2)a
N/A N/A 5 - 10,000 (1/x
2)
+ 100-fold dilution
100 - 10,000 (1/x2)
+ 1000-fold dilution
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Supplementary Table 7: Estimated EPCs for individual versus combination administration by dividing the dose of
butorphanol by the mean plasma clearance over a 24 hour period determined by either an NCA or NMLE (posthoc)
approach. The IPCs were determined by dividing the EPC by a factor of 500 and the IUC determined by multiplying the
IPC by the pseudo steady-state ratio of urine to plasma concentration (Rss). The detection times (DT) were determined by
the time post dose where all horses had concentrations below the IPC/IUC.
Parameter Individual Administration Combination Administration
NCA NLME NCA NLME
EPC (pg/mL) 6450 5995 2741 2692
IPC (pg/mL) 13 12 6 5
Rss 730 730 560 560
IUC (pg/mL) 9490 8760 3080 3015
Plasma DT (hrs) 49 49 >47 >47
Urine DT (hrs) 57 57 50 50
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Supplementary Table 8: Estimated EPCs for individual versus combination administration by dividing the dose of
detomidine by the mean plasma clearance over a 24 hour period determined by either an NCA or NMLE (posthoc)
approach. The IPCs were determined by dividing the EPC by a factor of 500 and the IUC determined by multiplying the
IPC by the pseudo steady-state ratio of urine to plasma concentration (Rss). The detection times (DT) were determined by
the time post dose where all horses had concentrations below the IPC/IUC.
Parameter Individual Administration Combination Administration
NCA NLME NCA NLME
EPC (pg/mL) 127 132 165 128
IPC (pg/mL) 0.25 0.26 0.33 0.27
Rss 4 4 8 8
IUC (pg/mL) 1.02 1.04 2.64 2.05
Plasma DT (hrs) >4 >4 >9 >9
Urine DT (hrs) >4 >4 11 11






